{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32462039", "DateCompleted": {"Year": "2021", "Month": "03", "Day": "08"}, "DateRevised": {"Year": "2021", "Month": "03", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "05", "Day": "12"}], "Language": ["eng"], "ELocationID": ["9631731", "10.1155/2020/9631731"], "Journal": {"ISSN": "2314-6141", "JournalIssue": {"Volume": "2020", "PubDate": {"Year": "2020"}}, "Title": "BioMed research international", "ISOAbbreviation": "Biomed Res Int"}, "ArticleTitle": "Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.", "Pagination": {"StartPage": "9631731", "MedlinePgn": "9631731"}, "Abstract": {"AbstractText": ["Hepatotoxicity is historically the 3<sup>rd</sup> most common reason for drug withdrawal and toxicity-related discontinuation of treatment. This study was aimed at determining the incidence and the onset of hepatotoxicity and at evaluating the relationship of some risk factors for hepatotoxicity among Human Immunodeficiency Virus- (HIV-) positive, tuberculosis (TB), and HIV/TB patients on treatment. This was a prospective follow-up study involving 125 participants from the HIV/AIDS and TB treatment centres in three hospitals in Fako Division of Cameroon. These TB and HIV patients were initiated on RHEZ (R\u2009=\u2009Rifampicin, H\u2009=\u2009Isoniazid, E\u2009=\u2009Ethambutol, and P\u2009=\u2009Pyrazinamide) and TELE (efavirenz/tenofovir/lamivudine), respectively, and followed up for 12 weeks between September 2018 and November 2019. The levels of liver enzymes (transaminases, gamma-glutamyltransferase, alkaline phosphatase, and unconjugated/total bilirubin) were measured spectrophotometrically using serum. The Chi-squared (<i>\u03c7</i> <sup>2</sup>) test was used to assess the association between risk factors and hepatotoxicity, while the Kaplan-Meier survival analysis with the log-rank test was used to determine the occurrence of hepatotoxicity in the different groups. We followed the general study population for a total person time of 6580 person-days, with an incidence rate and cumulative incidence of 8 cases per 1000 person-days (53/6580 person-days) and 42.4% (53/125), respectively (95% confidence interval), recorded after 12 weeks of follow-up of all the participants. The onset of hepatotoxicity in the total study population was statistically significant (<i>\u03c7</i> <sup>2</sup> = 9.5334; <i>p</i> = 0.022979; CI = 95%), with the majority observed at week eight of follow-up. Also, the incidence rate and cumulative incidence of hepatotoxicity with respect to HIV/AIDS, TB, and HIV/TB patients, respectively, at 95% confidence interval were: 8 cases per 1000 person-days (32/3843 person-days) and 32/76 (42.1%), 6 cases per 1000 person-days (12/1932 person-days) and 12/32 (37.5%), and 11 cases per 1000 person-days (9/805 person-days) and 9/17 (52.9%). This study shows that the incidence rate and cumulative incidence of hepatotoxicity in HIV/AIDS, TB, and HIV/TB patients on treatment were high in Fako Division, Cameroon. Also, it is very important to check these patients' liver function especially within the first 12 weeks of treatment."], "CopyrightInformation": "Copyright \u00a9 2020 Jude Eteneneng Enoh et al."}, "AuthorList": [{"Identifier": ["0000-0001-5941-0774"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Laboratory of Endocrinology and Radio-Elements, Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, P.O. Box 13033 Yaound\u00e9, Cameroon."}, {"Identifier": [], "Affiliation": "Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo."}], "LastName": "Enoh", "ForeName": "Jude Eteneneng", "Initials": "JE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo."}, {"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon."}], "LastName": "Cho", "ForeName": "Frederick Nchang", "Initials": "FN"}, {"Identifier": ["0000-0002-7056-7817"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon."}], "LastName": "Manfo", "ForeName": "Faustin Pascal", "Initials": "FP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Medical Research and Bacteriology Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}], "LastName": "Ako", "ForeName": "Simon Eyongabane", "Initials": "SE"}, {"Identifier": ["0000-0001-5587-6243"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon."}, {"Identifier": [], "Affiliation": "Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo."}, {"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon."}], "LastName": "Akum", "ForeName": "Eric Achidi", "Initials": "EA"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Biomed Res Int", "NlmUniqueID": "101600173"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-HIV Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antitubercular Agents"}, {"RegistryNumber": "EC 2.3.2.2", "NameOfSubstance": "gamma-Glutamyltransferase"}, {"RegistryNumber": "EC 2.3.2.2", "NameOfSubstance": "gamma-glutamyltransferase, human"}, {"RegistryNumber": "EC 2.6.1.-", "NameOfSubstance": "Transaminases"}, {"RegistryNumber": "EC 3.1.3.1", "NameOfSubstance": "Alkaline Phosphatase"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Alcohol Drinking"}, {"QualifierName": ["blood"], "DescriptorName": "Alkaline Phosphatase"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Anti-HIV Agents"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Antitubercular Agents"}, {"QualifierName": [], "DescriptorName": "Cameroon"}, {"QualifierName": ["blood", "etiology", "metabolism"], "DescriptorName": "Chemical and Drug Induced Liver Injury"}, {"QualifierName": [], "DescriptorName": "Coinfection"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["complications", "drug therapy", "epidemiology"], "DescriptorName": "HIV Infections"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["enzymology"], "DescriptorName": "Liver"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Risk Factors"}, {"QualifierName": ["blood"], "DescriptorName": "Transaminases"}, {"QualifierName": ["complications", "drug therapy", "epidemiology"], "DescriptorName": "Tuberculosis"}, {"QualifierName": ["blood"], "DescriptorName": "gamma-Glutamyltransferase"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Jameson J. L., Fauci A. S., Kasper D. L., Hauser S. L., Longo D. L., Loscalzo J. Harrison\u2019s Principles of Internal Medicine. 19th. McGraw-Hill Education: New York, NY, USA; 2015. Human immunodeficiency virus disease: AIDS and related disorders."}, {"Citation": "AIDS GOV. What are HIV and AIDS?  February 2019,  https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids."}, {"Citation": "World Health Organization. HIV/AIDS fact sheet: global health sector strategy on HIV, 2016-2021.  February 2018,  https://www.who.int/mediacentre/factsheets/fs360/en/"}, {"Citation": "United Nations Programme on HIV and AIDS (UNAIDS) Overview of Cameroon HIV stats (2018)  November 2019,  https://www.unaids.org/en/regionscountries/countries/cameroon."}, {"Citation": "World Health Organization. Global tuberculosis report 2018.  February 2019,  https://www.who.int/tb/en."}, {"Citation": "Karumbi J., Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database of Systematic Reviews. 2015;5 doi: 10.1002/14651858.CD003343.pub4.", "ArticleIdList": ["10.1002/14651858.CD003343.pub4", "PMC4460720", "26022367"]}, {"Citation": "Global Alliance for TB Drug Development. Handbook of Anti-Tuberculosis Agents. Tuberculosis. 2008;88(2):141\u2013144.", "ArticleIdList": ["0"]}, {"Citation": "Wu S., Zhang Y., Sun F., et al. Adverse events associated with the treatment of multidrug-resistant Tuberculosis. American Journal of Therapeutics. 2016;23(2):e521\u2013e530. doi: 10.1097/01.mjt.0000433951.09030.5a.", "ArticleIdList": ["10.1097/01.mjt.0000433951.09030.5a", "24284652"]}, {"Citation": "Jeong I., Park J.-S., Cho Y.-J., et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Journal of Korean Medical Science. 2015;30(2):167\u2013172. doi: 10.3346/jkms.2015.30.2.167.", "ArticleIdList": ["10.3346/jkms.2015.30.2.167", "PMC4310943", "25653488"]}, {"Citation": "Parsons L. M., Somoskovi A., Gutierrez C., et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical Microbiology Reviews. 2011;24(2):314\u2013350. doi: 10.1128/CMR.00059-10.", "ArticleIdList": ["10.1128/CMR.00059-10", "PMC3122496", "21482728"]}, {"Citation": "Shiferaw M. B., Tulu K. T., Zegeye A. M., Wubante A. A. Liver enzymes abnormalities among highly active antiretroviral therapy experienced and HAART na\u00efve HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: a comparative cross-sectional study. AIDS Research and Treatment. 2016;2016:7. doi: 10.1155/2016/1985452.1985452", "ArticleIdList": ["10.1155/2016/1985452", "PMC4963552", "27493798"]}, {"Citation": "Almazroo O. A., Miah M. K., Venkataramanan R. Drug metabolism in the liver. Clinics in Liver Disease. 2017;21(1):1\u201320. doi: 10.1016/j.cld.2016.08.001.", "ArticleIdList": ["10.1016/j.cld.2016.08.001", "27842765"]}, {"Citation": "Chen M., Suzuki A., Borlak J., Andrade R. J., Lucena M. I. Drug-induced liver injury: interactions between drug properties and host factors. Journal of Hepatology. 2015;63(2):503\u2013514. doi: 10.1016/j.jhep.2015.04.016.", "ArticleIdList": ["10.1016/j.jhep.2015.04.016", "25912521"]}, {"Citation": "Bjornsson E. S., Bergmann O. M., Bjornsson H. K., Kvaran R. B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419\u20131425.e3. doi: 10.1053/j.gastro.2013.02.006.", "ArticleIdList": ["10.1053/j.gastro.2013.02.006", "23419359"]}, {"Citation": "Bj\u00f6rnsson E. S. Incidence and outcomes of DILI in western patients. Clinical Liver Disease. 2014;4(1):9\u201311. doi: 10.1002/cld.368.", "ArticleIdList": ["10.1002/cld.368", "PMC6448724", "30992911"]}, {"Citation": "Assob J. C. N., Nde P. F., Nsagha D. S., Njunda A. L., Ngum N. M., Ngowe N. M. Incidence and risk factors of anti-tuberculosis drugs induced hepatotoxicity in HIV/AIDS patients attending the Limbe and Buea Regional Hospitals. Journal of AIDS and Clinical Research. 2014;5"}, {"Citation": "Lee C. M., Lee S. S., Lee J. M., et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. The Korean Journal of Internal Medicine. 2016;31(1):65\u201372. doi: 10.3904/kjim.2016.31.1.65.", "ArticleIdList": ["10.3904/kjim.2016.31.1.65", "PMC4712436", "26767859"]}, {"Citation": "Abera W., Cheneke W., Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. International Journal of Mycobacteriology. 2016;5(1):14\u201320. doi: 10.1016/j.ijmyco.2015.10.002.", "ArticleIdList": ["10.1016/j.ijmyco.2015.10.002", "26927985"]}, {"Citation": "World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 rev. Geneva, Switzerland: World Health Organization; 2006.   https://apps.who.int/iris/handle/10665/43554.", "ArticleIdList": ["23741771"]}, {"Citation": "Abbara A., Chitty S., Roe J. K., et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infectious Diseases. 2017;17(1):p. 231. doi: 10.1186/s12879-017-2330-z.", "ArticleIdList": ["10.1186/s12879-017-2330-z", "PMC5366108", "28340562"]}, {"Citation": "LiverTox. Clinical and research information on drug-induced liver injury. Bethesada: Severity Grading in Drug-Induced Liver Injury; 2019.   http://www.ncbinlm.nih.gov/books/"}, {"Citation": "Singh A., Bhat T. K., Sharma O. P. Clinical biochemistry of hepatotoxicity. Journal of Clinical Toxicology. 2014;4(1) doi: 10.4172/2161-0495.S4-001.", "ArticleIdList": ["10.4172/2161-0495.S4-001"]}, {"Citation": "Yang J. J., Huang C. H., Liu C. E., et al. Multicenter study of trimethoprim/sulfamethoxazole related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One. 2014;9(9, article e106141) doi: 10.1371/journal.pone.0106141.", "ArticleIdList": ["10.1371/journal.pone.0106141", "PMC4153565", "25184238"]}, {"Citation": "Castro-Sanchez E., Chang P. W. S., Vila-Candel R., Escobedo A. A., Holmes A. H. Health literacy and infectious diseases: why does it matter? International Journal of Infectious Diseases. 2016;43:103\u2013110. doi: 10.1016/j.ijid.2015.12.019.", "ArticleIdList": ["10.1016/j.ijid.2015.12.019", "26751238"]}, {"Citation": "Ara\u00fajo-Mariz C., Lopes E. P., Acioli-Santos B., et al. Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. PLoS One. 2016;11(6, article e0157725) doi: 10.1371/journal.pone.0157725.", "ArticleIdList": ["10.1371/journal.pone.0157725", "PMC4917242", "27332812"]}, {"Citation": "Isa S. E., Ebonyi A. O., Shehu N. Y., et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. International Journal of Mycobacteriology. 2016;5(1):21\u201326. doi: 10.1016/j.ijmyco.2015.10.001.", "ArticleIdList": ["10.1016/j.ijmyco.2015.10.001", "26927986"]}, {"Citation": "Ngongondo M. N., Miyahara S., Hughes M. D., et al. Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe Immunosuppression. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;78(1):54\u201361. doi: 10.1097/qai.0000000000001641.", "ArticleIdList": ["10.1097/qai.0000000000001641", "PMC5889344", "29406428"]}, {"Citation": "Raghu R., Karthikeyan S. Zidovudine and isoniazid induced liver toxicity and oxidative stress: evaluation of mitigating properties of silibinin. Environmental Toxicology and Pharmacology. 2016;46:217\u2013226. doi: 10.1016/j.etap.2016.07.014.", "ArticleIdList": ["10.1016/j.etap.2016.07.014", "27497728"]}, {"Citation": "Stine J. G., Chalasani N. P. Drug Hepatotoxicity: Environmental Factors. Clinics in Liver Disease. 2017;21(1):103\u2013113. doi: 10.1016/j.cld.2016.08.008.", "ArticleIdList": ["10.1016/j.cld.2016.08.008", "PMC6600816", "27842766"]}, {"Citation": "Golemba A. S., et al. Ferreyra F. G. E., Martearena R. E., Achinelli F. R., Rovai G. B. Drug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast. Medwave. 2015;15(4, article e6135) doi: 10.5867/medwave.2015.04.6135.", "ArticleIdList": ["10.5867/medwave.2015.04.6135", "26035138"]}, {"Citation": "Hunt C. M., Westerkam W. R., Stave G. M. Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology. 1992;44(2):275\u2013283. doi: 10.1016/0006-2952(92)90010-g.", "ArticleIdList": ["10.1016/0006-2952(92)90010-g", "1642641"]}, {"Citation": "Hosford J. D., von Fricken M. E., Lauzardo M., et al. Hepatotoxicity from antituberculous therapy in the elderly: A systematic review. Tuberculosis. 2015;95(2):112\u2013122. doi: 10.1016/j.tube.2014.10.006.", "ArticleIdList": ["10.1016/j.tube.2014.10.006", "PMC4640443", "25595441"]}, {"Citation": "Khoury T., et al. Drug-induced liver injury: review with a focus on genetic factors, tissue diagnosis, and treatment options. Journal of Clinical and Translational Hepatology. 2015;3:99\u2013108.", "ArticleIdList": ["PMC4548351", "26356634"]}]}], "History": [{"Year": "2020", "Month": "1", "Day": "16"}, {"Year": "2020", "Month": "4", "Day": "4"}, {"Year": "2020", "Month": "4", "Day": "29"}, {"Year": "2020", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "5", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["32462039", "PMC7243024", "10.1155/2020/9631731"]}}]}